**Title:** Clinical Manifestations of COVID-19 Breakthrough Infections: A Systematic Review and Meta-Analysis

**Authors and Affiliations:** Christine J. Lee1†**,** Wongi Woo2†, Ah Young Kim3,13†, Dong Keon Yon4, Seung Won Lee5, Ai Koyanagi6,7, Min Seo Kim8, KalthoumTizaoui9, Elena Dragioti10, Joaquim Radua11,14,15, Sungsoo Lee2, Lee Smith12,Jae Il Shin13**\***

1. Department of Biological and Chemical Sciences, New York Institute of Technology, Old Westbury, USA

2. Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

3. Division of Pediatric Cardiology, Department of Pediatrics, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea

4. Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea  
5. Department of Data Science, Sejong University College of Software Convergence, Seoul, South Korea

6. Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain  
7. ICREA, Pg. Lluis Companys 23, Barcelona, Spain  
8. Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea  
9. Laboratory of Microoranismes and Active Biomolecules, Sciences Faculty of Tunis, Tunis El Manar University, Tunis, Tunisia  
10. Pain and Rehabilitation Centre, and Department of Medical and Health Sciences, Linköping University, SE-581 85 Linköping, Sweden

11. Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institute, Stockholm, Sweden  
12. Cambridge Centre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, UK  
13. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea

14. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERSAM, Barcelona, Spain.

15. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

**Word Count:** 2613

**Corresponding Author:**

Jae Il Shin, M.D., Ph.D.  
Address: 50 Yonsei-ro, Seodaemun-gu, C.P.O. Box 8044, Department of Pediatrics, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea  
Tel: +82-2-2228-2050; Fax: +82-2-393-9118; E-mail: [shinji@yuhs.ac](mailto:shinji@yuhs.ac)

# Abstract

**Objective:** To provide a comparative meta-analysis and systematic review of the risk and clinical outcomes of COVID-19 infection between fully vaccinated and unvaccinated groups.

**Methods:** Eighteen studies of COVID-19 infections in fully vaccinated (“breakthrough infections”) and unvaccinated individuals were reviewed from Medline/PubMed, Scopus, Embase, and Web of Science databases. The meta-analysis examined the summary effects and between-study heterogeneity regarding differences in the risk of infection, hospitalization, treatments, and mortality between vaccinated and unvaccinated individuals .

**Results:** The overall risk of infection was lower for the fully vaccinated compared to that of the unvaccinated (relative risk[RR] 0.20, 95% CI 0.19-0.21), especially for variants other than Delta (Delta: RR 0.29, 95% CI 0.13-0.65; other variants: RR 0.06, 95% CI 0.04-0.08). The risk of asymptomatic infection was not statistically significantly different between fully vaccinated and unvaccinated (RR 0.56, 95% CI 0.27-1.19). There were neither statistically significant differences in risk of hospitalization (RR 1.06, 95% CI 0.38-2.93), invasive mechanical ventilation (RR 1.65 ,95% CI 0.90-3.06), or mortality (RR 1.19, 95% CI 0.79-1.78). Conversely, the risk of supplemental oxygen during hospitalization was significantly higher for the unvaccinated (RR 1.40, 95% CI 1.08-1.82).

**Conclusions:** Unvaccinated people were more vulnerable to COVID-19 infection than fully vaccinated for all variants. Once infected, there were no statistically significant differences in the risk of hospitalization, invasive mechanical ventilation, or mortality. Still, unvaccinated showed an increased need for oxygen supplementation. Further prospective analysis, including patients’ risk factors, COVID-19 variants, and the utilized treatment strategies, would be warranted.

**Keywords:** COVID-19, Delta Variant, Vaccine Effectiveness, Breakthrough Infection, Clinical Manifestations

# Introduction

The novel coronavirus, SARS-CoV-2, continues to restructure local health systems, disrupt global economies, and pervade all aspects of community life. Due to the universal concerns surrounding the virus and the unsettling nature of its accelerated spread, finding prevention options has become a priority. The development of the COVID-19 vaccine was a major milestone towards the possible end of the pandemic. However, the ever-evolving nature of the virus through a multitude of mutative evolutionary events has posed a concern for vaccine efficacy due to viral genomic changes. Thus, the questions surrounding the sustainability of the approved COVID-19 vaccines remain a concern against continually rising viral variants.

The more recent variant of concern, the Delta variant, appears to consist of 5 different sublinegaes to date (B.1.617.2, AY.1, AY.2, AY.3, and AY.3.1)1. All Delta variant sublineages share the main mutations of concern, T478K and L452R1. A recent case in Lombardy, Italy has indicated the presence of the E484K mutation on the B.1.617.2 sublineage causing novel resistance to monoclonal antibody treatment options and a substantial decrease in vaccine efficacy1. Due to the widespread convergent evolutionary trends, it can be expected that this mutation will spread through all variant types. Monitoring both emerging variants and viral evolutionary patterns are necessary to understand the current state of the pandemic. Further, it is vital to reevaluate the efficacy of vaccines to improve the prevention protocols in the future.

Previous studies have reported varying clinical outcomes for both vaccinated and unvaccinated groups. In Israel, vaccinations across all ages were observed to be highly effective in preventing both symptomatic and asymptomatic infections, hospitalization, severe disease, and death2. Another study found significant decline in vaccine effectiveness with age and with existing comorbidities such as type 2 diabetes, chronic obstructive pulmonary disease, immunosuppression and cardiac disease3. Due to the variability of findings, it is imperative to determine a cohesive view of the clinical outcomes for both vaccinated and unvaccinated individuals.

In this study, we comparatively analyze vaccinated and unvaccinated individuals to understand the effectiveness of COVID-19 vaccination through examining their respective clinical outcomes while including the Delta variant. Through the meta-analysis and systemic review format, numerous scientific publications will be used to provide a comprehensive view of what is known regarding vaccine effectiveness through the Delta variant. It is anticipated that the data derived from this study can be used to drive policy decisions, promote prevention innovations, and contribute towards the end of the pandemic.

# Methods

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist (Supplementary Table S1), and this study was not registered with PROSPERO due to concerns about exposure of ideas related to timely and important research topics.

## Literature Search Strategy and Study Selection

We searched Medline/PubMed, Scopus, Embase, and Web of Science databases up to December 7, 2021. The search terms used are described in Supplementary Table S2. Three authors (CL, WW, AYK) independently screened title/abstracts and the fourth author (JIS) resolved any disagreements. The full literature search strategy is presented in Supplementary Figure S1. The eligibility criteria for inclusion were as follows: (1) studies in which SARS-CoV-2 infection among fully vaccinated and unvaccinated individuals were compared; (2) studies about the incidence of infection in individuals according to their vaccination status ;(3) a short survey, or monthly report with clinical data for SARS-CoV-2 infection in the fully vaccinated and unvaccinated groups. We excluded (1) studies where partially vaccinated cases were mixed with vaccinated groups; (2) case series and those relating to booster vaccinations; (3) laboratory studies without sufficient data; (4) review articles, letters to the editors, abstracts, articles that did not contain sufficient information on patients; (5) studies with limited information about breakthrough infection; (6) studies with insufficient clinical data.

## Data Extraction and Statistical Analysis

Four authors (CL, WW, AYK, and JIS) extracted data, including study author, year, country, dates, population, study design, sample size, type of variant, demographic factors (age, gender, race, comorbidity), and clinical outcomes (infection incidence, proportion of asymptomatic infection/ hospitalization/ patients needing intensive care/ mortality). Throughout the article, vaccinated means fully vaccinated individuals who received their primary series of COVID-19 vaccines; for example, persons after two weeks from their second dose of a messenger RNA vaccine such as Pfizer-BioNTech or Moderna.

The risks of infection, hospitalization, oxygen requirement, invasive mechanical ventilation, and mortality were expressed as relative risk (RR) and 95% confidence interval. Random effects model was used to demonstrate each comparison between unvaccinated and fully vaccinated groups. Heterogeneity among studies was expressed as I2 (values over 50% are commonly considered to represent significant heterogeneity). All tests were 2-sided; an alpha level of .05 was chosen for significance. Statistical analyses were performed using R version 4.1.0 (R Foundation for Statistical Computing, Vienna, Austria) and the Review Manager (RevMan) software version 5.2.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).

# Results

The initial search identified 1025 studies which included comparative studies, epidemiology focused studies, infectivity analyses, laboratory studies, modeling studies and outcome-based studies. We excluded studies with irrelevant data and not responding to inclusion criteria. The PRISMA flow model for study selection is shown in Supplementary Figure S1. Finally, 18 studies were included in the synthesis of the meta-analysis and systemic review456789101112131415161718192021. Findings of each included study are described in Supplementary Table S3.

The clinical outcomes according to vaccination status in each study are demonstrated in Tables 1-2. Figures 1(a-c) examined the risk of SARS-CoV-2 infection among exposed individuals according to vaccination status for the Delta variant, non-Delta variants and all variants, respectively. Figure 1(a) (the Delta variant) indicated an RR of 0.29 [95%-CI: 0.13-0.65] among the fully vaccinated individuals compared to the unvaccinated ones when exposed to the Delta variant under the random effects model (). Figure 1(b) (other than the Delta variant) indicated an RR of 0.06 [95%-CI: 0.04-0.08] under the random effects model (). When including all variants (Figure 1(c)), the risk of infection among the fully vaccinated presented an RR of 0.18 [95% CI: 0.10-0.33] with significant heterogeneity among included studies (). Universally, vaccinated individuals were still less likely to be infected when in contact with all variants of SARS-CoV-2. However, the beneficial effect diminished in the Delta variant when compared to others.

The risk of asymptomatic infection according to vaccination status for all variants is shown in Figure 2. The RR was 0.56 [95%-CI: 0.27-1.19] under the random effects model (indicating no difference in asymptomatic infection risk between vaccinated and unvaccinated groups.Figure 3 shows the risk of hospitalization according to vaccination status in all variants. The RR was 1.06 [95%-CI: 0.38-2.93] in the fully vaccinated when compared to the unvaccinated group under the random effects model ( ).

After being hospitalized, the risk of oxygen requirement in unvaccinated patients was 1.40 [95%-CI: 1.08-1.82] under the random effects model ( (Figure 4.). Note, Chia et al22 and Bierle et al23 only contributed Delta variant data sets to this figure. Figure 5 described the risk of invasive mechanical ventilation among the unvaccinated (RR 1.65 [95%-CI: 0.90-3.06], ), which seemed marginally significant. Notably, the mortality risk in the unvaccinated after being hospitalized presented a RR of 1.19 [95%-CI: 0.79-1.78] as shown in Figure 6. Heterogeneity was measured at indicating consistent findings within studies included for this analysis. In partially vaccinated patients, the risk of supplemental oxygen treatments (RR 1.00 [95% CI :0.95-1.05], I2=0%) and mortality (RR 0.78 [95% CI : 0.21-2.88], I2=74%) was not different compared to unvaccinated (Supplemental Table S4, Supplementary Figure S 2-3).

Table 3 describes the demographic characteristics of the patients included in each study. Significant differences between vaccinated and unvaccinated patients were found except for the study by Butt et al.24 in which the propensity score was matched for demographic variables. The average median age range of patients in vaccinated and unvaccinated groups were between 45-70.3 and 39.5-59.6 years, respectively. The proportion of male in infected patients were similar between fully vaccinated and unvaccinated (Supplementary Figure S4). The race of participants found within both vaccinated and unvaccinated cohorts included Hispanic, Black, White, and other unnamed groups. Underlying health conditions were also assessed including hypertension, diabetes, chronic lung disease, immunosuppression, and transplantation. In addition, the information regarding seropositivity only from three available studies was described in Supplementary Table S5. These differences might explain the heterogeneity observed among studies.

# Discussion

The implementation of public health policies and rapid vaccination programs have proven to substantially diminish the spread of COVID-19. However, due to mutative evolutionary events, the virus has found ways to accelerate its spread despite these safety measures in place. More alarmingly, the COVID-19 vaccine has shown a reduction in efficacy against both time and ever-evolving variants. Therefore, it is imperative to consider the clinical outcomes of both vaccinated and unvaccinated groups to determine COVID-19 vaccine effectiveness against the current state of the pandemic.

The present study focused on comparing clinical outcomes in both vaccinated and unvaccinated individuals in two phases – risk of infection and hospitalization. This study presents itself as the first meta-analysis and systemic review to date focused on comparing vaccinated and unvaccinated individuals during the Delta variant dominant period. Our comparative analysis will determine the true effectiveness of the COVID-19 vaccine through their respective clinical outcomes.

Compared to other variants of concern, the Delta variant presents itself as highly transmissible, easily contractible, and moderately resistant to vaccination. The emergence of the Delta variant has resulted in an estimated 76% transmission advantage over the Alpha variant leading to major public health concerns25. The substantially higher risk ratio of 0.29 found in Figure 1(a) compared to the 0.05 and 0.20 risk ratios found in Figures 1(b) and 1(c) respectively indicate a greater risk of infection for vaccinated individuals when exposed to the Delta variant. Supporting the higher risk of infection when exposed to the Delta variant even in vaccinated groups is congruent with a study finding smaller reductions in vaccine-associated transmission when comparing the Delta and Alpha variants26. Despite this, there is still a minimal risk of transmission between symptomatic breakthrough cases to close household contacts27. Further, evidence points towards a faster mean rate of viral load decline among vaccinated individuals infected with the Delta variant compared to unvaccinated individuals infected with pre-Alpha, Alpha or the Delta variant alluding to vaccine efficacy28. Nevertheless, unvaccinated individuals are still more vulnerable to infection compared to their vaccinated counterparts.

COVID-19 infection can be classified as asymptomatic and symptomatic cases. The minimal difference found in Figure 2 between vaccinated and unvaccinated groups in terms risk of asymptomatic infection allude to no effect of vaccination status in this case. However, a Delta variant specific study conducted in Guangzhou, China found milder clinical symptoms in partially and fully vaccinated individuals compared to unvaccinated individuals29. Further supporting this study, higher vaccine effectiveness against serious COVID-19 disease such as symptomatic cases have been observed against Alpha and Beta variants30. Despite this, negligible differences were found between vaccinated and unvaccinated groups for risk of asymptomatic cases for all variants in this study.

The risk of hospitalization, oxygen requirement, invasive mechanical ventilation, and mortality were all considered to be measures of disease severity when comparing infected vaccinated and unvaccinated individuals in our study. Figure 3 showed no difference in risk of hospitalization for all variants when comparing vaccination status thereby indicating negligible vaccine efficacy in this regard. However, according to Figure 4, risk of oxygen requirement was higher in unvaccinated individuals when compared to vaccinated individuals. Clinical severity in unvaccinated groups compared to vaccinated groups have been examined in terms of risk of febrile symptoms and illness duration in a previous study. It was found that among infected individuals, the risk of febrile symptoms was 58% lower and the duration of illness was shorter with 2.3 fewer days spent in bed when comparing vaccinated individuals to the unvaccinated ones31. Similarly to Figure 3, Figure 4 showed negligible differences in risk of invasive mechanical ventilation when comparing for vaccination status. Lastly, the risk of mortality when comparing vaccinated and unvaccinated groups remained non-significant as shown in Figure 6. In the Yogyakarta and Central Java provinces in Indonesia, related findings were found indicating no significant difference in the hospitalization and mortality rates of patients infected with the Delta and non-Delta variants32. Nevertheless, the Delta variant still presents itself as a more severe infection when compared to the Beta variant, however, evidence alludes to a protective nature of vaccination against severe outcomes for both variants of concern supporting claims of vaccine efficacy333435.

This study also examined the role of comorbidities including hypertension, diabetes, chronic lung disease, immunosuppression, and transplantation on risk of infection and clinical severity. As Table 3 demonstrated the median or mean age of included studies ranged from 45 to 70.3 and the proportion of patients with hypertension was also different (range : 19.7% to 75.2%). Other than this, the variable medical conditions in each study should be considered in interpreting the result. Another study reported that vaccine breakthrough infections with the Alpha and Delta variants were associated with comorbidities such as hypertension, immunosuppression, cancer, and coronary heart disease36. Further, the rate of severe or critical disease has been found to be higher among older individuals with comorbidities in previous studies alluding to the importance of underlying patient health and well-being when concerned with COVID-19 infection37. In a recently published study, the role of gender was stressed as a predictor for breakthrough infection38 and there were several plausible explanation describing gender-related difference in angiotensin-converting-enzyme-2 expression39,40, estrogen, X-chromosome41,42, and behavioral patterns in precautionary measures for COVID-19 prevention43,44. As the virus continues to mutate, it is important to monitor, understand and further analyze the respective clinical outcomes of both vaccinated and unvaccinated groups for future variants to come.

There are several limitations to this study. First, the high level of heterogeneity found in this study indicates inconsistencies within included studies. Due to the limited number of studies, we could not compare the results according to study design such as prospective or cross-sectional studies. Therefore, cautious interpretation of the results would be warranted. Additionally, the conflicting findings found within included studies make it harder to justify conclusions being made within the study. Second, some of the included studies examined specific variants thereby skewing the findings to one variant of concern. This unbalanced representation makes it harder to generalize conclusions for all variants of concern. Third, we could not match the differences in patient demographics or risk factors for SARS-CoV-2 infection. Since heterogeneity was present in comorbidities, we could not adjust these parameters when comparing clinical outcomes. Only one study provided substantial results after adjustments. Specifically, seropositivity data was not accessible in most studies. The different positivity in IgG antibody against COVID-19 could affect the results in clinical outcome. Therefore, further prospective studies which adjust for the baseline characteristics of patients would be necessary to evaluate vaccine efficacy more precisely. Additionally, this study is limited to deliver significant meaning in partially vaccinated patients as only two available data sources were integrated in the meta-analysis.

# Conclusion

This study is the first meta-analysis and systematic review focused on comparing the clinical outcomes of vaccinated and unvaccinated individuals within the Delta dominant period to date. The study findings indicated greater risk of unvaccinated individuals for SARS-CoV-2 infection and oxygen requirement compared to vaccinated individuals and negligible differences between groups for risk of asymptomatic infection, hospitalization, invasive mechanical ventilation, and mortality. Due to limited patient information and the heterogeneity among included studies, further prospective well-adjusted studies are necessary to evaluate vaccine efficacy against variants of concern to come.

**Funding Support:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflict of Interest:** The authors disclose no financial or non-financial conflicts of interest, including funding, provision of study materials, medical writing, and article processing charges.

**Ethical Approval Statement:** Not applicable.

**Authors’ Contributions:**

**Christine J. Lee:** Conceptualization, Methodology, Data Curation, Formal analysis, Resources, Investigation, Writing - Original Draft, Writing – Review & Editing. **Wongi Woo:** Conceptualization, Methodology, Data Curation, Formal analysis, Investigation, Software, Writing - Original Draft, Writing – Review & Editing. **Ah Young Kim:** Conceptualization, Methodology, Data Curation, Formal analysis, Writing - Original Draft, Writing – Review & Editing. **Dong Keon Yon:** Writing – Review & Editing. **Seung Won Lee:** Writing – Review & Editing. **Ai Koyanagi:** Writing – Review & Editing. **Min Seo Kim:** Writing – Review & Editing. **Sungsoo Lee:** Writing – Review & Editing. **Jae Il Shin:** Conceptualization, Methodology, Validation, Supervision, Project administration Writing – Review & Editing. **Smith Lee:** Writing – Review & Editing.

**Acknowledgements:**

No acknowledgements.

**Data Availability Statement:**

The data underlying this article will be shared by the corresponding author on reasonable request.

# References

1. Baj A, Novazzi F, Pasciuta R, et al. Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy. *Emerg Infect Dis*. 2021;27(12):3180-3182. doi:10.3201/eid2712.211792

2. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *The Lancet*. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8

3. Yelin I, Katz R, Herzel E, et al. *Associations of the BNT162b2 COVID-19 Vaccine Effectiveness with Patient Age and Comorbidities*. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.03.16.21253686

4. Naito T, Yan Y, Tabe Y, Seyama K, Deshpande GA. Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan. *Hum Vaccines Immunother*. Published online October 6, 2021:1-2. doi:10.1080/21645515.2021.1984124

5. Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(34):1167-1169. doi:10.15585/mmwr.mm7034e4

6. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet*. 2021;397(10293):2461-2462. doi:10.1016/S0140-6736(21)01358-1

7. Ghosh S, Shankar S, Chatterjee K, et al. COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study. *Med J Armed Forces India*. 2021;77:S264-S270. doi:10.1016/j.mjafi.2021.06.032

8. Waldman SE, Buehring T, Escobar DJ, et al. Secondary Cases of Delta Variant Coronavirus Disease 2019 Among Vaccinated Healthcare Workers With Breakthrough Infections is Rare. *Clin Infect Dis*. Published online October 25, 2021:ciab916. doi:10.1093/cid/ciab916

9. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. *JAMA*. 2021;326(20):2043. doi:10.1001/jama.2021.19499

10. Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. *Clin Microbiol Infect*. Published online November 2021:S1198743X21006388. doi:10.1016/j.cmi.2021.11.010

11. Thangaraj JWV, Yadav P, Kumar CG, et al. Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021. *J Infect*. 2022;84(1):94-118. doi:10.1016/j.jinf.2021.08.006

12. Shamier MC, Tostmann A, Bogers S, et al. *Virological Characteristics of SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers*. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.08.20.21262158

13. Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipients. *Transpl Infect Dis*. 2021;23(5). doi:10.1111/tid.13705

14. Christensen PA, Olsen RJ, Long SW, et al. Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. *Am J Pathol*. Published online November 2021:S0002944021004806. doi:10.1016/j.ajpath.2021.10.019

15. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. *J Clin Virol*. 2021;145:105026. doi:10.1016/j.jcv.2021.105026

16. Butt AA, Yan P, Shaikh OS, Mayr FB. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. *EClinicalMedicine*. 2021;40:101117. doi:10.1016/j.eclinm.2021.101117

17. Butt AA, Nafady-Hego H, Chemaitelly H, et al. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. *Int J Infect Dis*. 2021;110:353-358. doi:10.1016/j.ijid.2021.08.008

18. Liu C, Lee J, Ta C, et al. *A Retrospective Analysis of COVID-19 MRNA Vaccine Breakthrough Infections – Risk Factors and Vaccine Effectiveness*. Health Informatics; 2021. doi:10.1101/2021.10.05.21264583

19. Bosch W, Cowart JB, Bhakta S, et al. Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021. *Clin Infect Dis*. Published online November 2, 2021:ciab932. doi:10.1093/cid/ciab932

20. Taylor CA, Patel K, Pham H, et al. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(43):1513-1519. doi:10.15585/mmwr.mm7043e1

21. Bahl A, Johnson S, Maine G, et al. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. *Lancet Reg Health - Am*. 2021;4:100065. doi:10.1016/j.lana.2021.100065

22. Chia PY, Xiang Ong SW, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. *Clin Microbiol Infect*. Published online November 23, 2021. doi:10.1016/j.cmi.2021.11.010

23. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2021;145:105026. doi:10.1016/j.jcv.2021.105026

24. Butt AA, Nafady-Hego H, Chemaitelly H, et al. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. *Int J Infect Dis*. 2021;110:353-358. doi:10.1016/j.ijid.2021.08.008

25. Sonabend R, Whittles LK, Imai N, et al. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study. *The Lancet*. 2021;398(10313):1825-1835. doi:10.1016/S0140-6736(21)02276-5

26. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. *N Engl J Med*. Published online January 5, 2022:NEJMoa2116597. doi:10.1056/NEJMoa2116597

27. Sachdev DD, Chew Ng R, Sankaran M, et al. Contact tracing outcomes among household contacts of fully vaccinated COVID-19 patients — San Francisco, California, January 29-July 2, 2021. *Clin Infect Dis*. Published online December 20, 2021:ciab1042. doi:10.1093/cid/ciab1042

28. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infect Dis*. Published online October 2021:S1473309921006484. doi:10.1016/S1473-3099(21)00648-4

29. Li L, Han ZG, Qin PZ, et al. Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study. Lau SKP, ed. *PLoS Negl Trop Dis*. 2022;16(1):e0010048. doi:10.1371/journal.pntd.0010048

30. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med*. 2021;27(12):2136-2143. doi:10.1038/s41591-021-01583-4

31. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *N Engl J Med*. 2021;385(4):320-329. doi:10.1056/NEJMoa2107058

32. Gunadi null, Hakim MS, Wibawa H, et al. Is the Infection of the SARS-CoV-2 Delta Variant Associated With the Outcomes of COVID-19 Patients? *Front Med*. 2021;8:780611. doi:10.3389/fmed.2021.780611

33. Butt AA, Dargham SR, Chemaitelly H, et al. Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. *JAMA Intern Med*. Published online December 22, 2021. doi:10.1001/jamainternmed.2021.7949

34. Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(9):326-328. doi:10.15585/mmwr.mm7009e3

35. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

36. Luo CH, Morris CP, Sachithanandham J, et al. Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Recovery of Infectious Virus Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals. *Clin Infect Dis*. Published online December 18, 2021:ciab986. doi:10.1093/cid/ciab986

37. Butt AA, Yan P, Shaikh OS, Mayr FB, Omer SB. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population. *Clin Infect Dis*. Published online December 10, 2021:ciab1023. doi:10.1093/cid/ciab1023

38. Arora G, Taneja J, Bhardwaj P, et al. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population. *J Med Virol*. n/a(n/a). doi:10.1002/jmv.27708

39. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? *SN Compr Clin Med*. 2020;2(7):874-876. doi:10.1007/s42399-020-00341-w

40. Bukowska A, Spiller L, Wolke C, et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. *Exp Biol Med Maywood NJ*. 2017;242(14):1412-1423. doi:10.1177/1535370217718808

41. Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? *Int J Mol Sci*. 2020;21(10):E3474. doi:10.3390/ijms21103474

42. Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. *Cell Death Discov*. 2020;6:37. doi:10.1038/s41420-020-0276-1

43. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. *J Biol Regul Homeost Agents*. 2020;34(2):339-343. doi:10.23812/Editorial-Conti-3

44. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. *Aging Cell*. 2015;14(3):309-321. doi:10.1111/acel.12326

# Tables and Figures

**Figure Legends:**

Figure 1.

1. The risk of SARS-CoV-2 infection among exposed people according to vaccination status (Delta Variant)
2. The risk of SARS-CoV-2 infection among exposed people according to vaccination status (Other Variants)
3. The risk of SARS-CoV-2 infection among exposed people according to vaccination status (All Variants)

Figure 2. The risk of asymptomatic infection according to vaccination status (All Variants)

Figure 3. The risk of hospitalization according to vaccination status (All Variants)

Figure 4. The risk of oxygen requirement among hospitalized SARS-CoV-2 patients (All Variants)

Figure 5. The risk of invasive mechanical ventilation among hospitalized SARS-CoV-2 patients (All Variants)

Figure 6. The risk of mortality among hospitalized SARS-CoV-2 patients (All Variants)

**Table 1. The number of infected cases and asymptomatic infection according to the vaccination status**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | **Infected cases** | | | |  | **Asymptomatic/infected** | |
|  |  |  |  |  | *Breakthrough* | | *Unvaccinated* | |  | *Breakthrough* | *Unvaccinated* |
| Author | Country | Study type | Variants | Vaccine types | Delta | Others | Delta | Others |  |  |  |
| Bosch | USA | Retrospective | Delta, pre-Delta¶ | mRNA, J&J | 1089 | 31 | 5041 | |  |  | |
| Naito | Japan (HW) | Prospective cohort | Delta, pre-Delta¶ | mRNA | 3/2809 | 0/2809 | 19/5883 | 13/5883 |  |
| Fowlkes | USA | Prospective cohort | Delta, pre-Delta¶ | mRNA, J&J | 24/2352 | 10/2875 | 19/488 | 175/4137 |  |
| Sheikh | Scotland | Prospective cohort | Delta, pre-Delta¶ | BNT162b2  ChAdOx1 | BNT162b2 :  208/53679  ChAdOx1 :  231/32719 | BNT162b2 :  104/53575  ChAdOx1 :  100/32588 | 3672  /117263 | 5828 /119419 |  |
| Ghosh | India | Prospective cohort | Beta | ChAdOx1 | 2512 /1312938 | | 10061 /1595630 | |  |
| Waldman | USA (HW) | Cross-sectional | Delta | mRNA, J&J | 309/72624 |  | 131/15946 |  |  |
| Taylor | USA | Cross-sectional | Delta | mRNA. J&J |  |  |  |  |  |
| Tenforde | USA | Case-control | Alpha, Delta and others | mRNA |  |  |  |  |  |
| Bahl | USA | Observational cohort study | Alpha | mRNA. J&J |  | 129 |  | 10880 |  |
| Liu | USA | Observational, retrospective | Not specified | mRNA | 198 /14362 | | 3902 /37752 | |  |
| Chia | Singapore | Retrospective | Alpha, Beta, Delta, Gamma | mRNA | 71 |  | 130 |  |  | 20/71 | 12/130 |
| Thangaraj | India | Prospective cohort | Delta, Kappa, Alpha, Beta | ChAdOx1 COVAXIN | 84 | 3 | 134 | 17 |  | 12/104 | 10/176 |
| Butt | Qatar | Case-control | Delta and Beta | BNT162b2 |  | 456 |  | 456 |  | 216/456α | 204/456α |
| Shamier | Netherland | Retrospective | Alpha, Beta, Delta and Gamma | mRNA  Astra  J&J | 114 | 47 |  |  |  | 21/157 |  |
| Butt | USA | Case-control | Alpha, Beta and Delta | mRNA |  | 250 |  | 250 |  |  | |
| Aslam | USA | Retrospective cohort | Not specified | mRNA  J&J |  | 4/912 |  | 59/1151 |  |
| Christensen | USA | Retrospective | Delta and Alpha | mRNA  J&J | 3088 | 258 | 9483 | 3509 |  |
| Bierle | USA | Retrospective | Delta | mRNA  J&J | 201 |  | 429 |  |  |

HW, healthcare workers; IMV, invasive mechanical ventilation; NIPPV, non-invasive positive pressure ventilation; ECMO, extracorporeal membrane oxygenation  
All data are expressed as n, n/N  
¶ Pre-Delta means any variant other than the Delta variant that was dominant before the Delta variant was most likely.  
α, Variants other than delta  
δ, data from delta variant only

**Table 2.Comparison of Clinical outcome and severity according to the vaccination status**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | **Hospitalization/Infected** | | | |  | **Oxygen treatment** | | | |  | **Intensive care/Hospitalized** | | | |  | **Mortality/Hospitalized** | | | | |
|  |  |  |  | *Breakthrough* | | *Unvaccinated* | |  | *Breakthrough* | | *Unvaccinated* | |  | *Breakthrough* | | *Unvaccinated* | |  | *Breakthrough* | | *Unvaccinated* | | |
| Author | Country | Variants | Vaccine types | Delta | Others | Delta | Others |  | Delta | Others | Delta | Others |  | Delta | Others | Delta | Others |  | Delta | Others | Delta | Others |
| Bosch | USA | Delta,  pre-Delta¶ | mRNA, J&J | 119/1089 | 7/31 | 505 | 334 |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Naito | Japan (HW) | Delta,  pre-Delta¶ | mRNA |  |  |  |  |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Fowlkes | USA | Delta,  pre-Delta¶ | mRNA, J&J |  |  |  |  |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Sheikh | Scotland | Delta,  pre-Delta¶ | BNT162b2  ChAdOx1 | Alpha : 223/9996 infected  Delta : 134/7723 infected | | | |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Ghosh | India | Beta | ChAdOx1 |  |  |  |  |  |  | |  | |  |  |  |  |  |  | 7 /2512 infected | | 37 /10061 infected | |
| Waldman | USA (HW) | Delta | mRNA, J&J |  |  |  |  |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Taylor | USA | Delta | mRNA. J&J | 393 | 389 | 1145 | 4896 |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Tenforde | USA | Alpha, Delta and others | mRNA | 191 | 123 | 666 | 1003 |  | 98/142 | | 889/1055 | |  | **35/142**  IMV 11/142  NIPPV 20/142  ECMO 1/142 | | **423/1055**  IMV 243/1055  NIPPV 182/1055  ECMO 39/1055 | |  | 9/142 | | 91/1055 | |
| Bahl | USA | Alpha | mRNA. J&J |  | 95/129 |  | 5250/10880 |  | 64/95α | | 4042/5250 α | |  | IMV 6/95α  NIPPV 10/95α  ECMO 0/95α | | IMV 395/5250α  NIPPV 428/5250α  ECMO 4/5250α | |  | 8/95 α | | 379/5250 α | |
| Liu | USA | Not specified | mRNA | 120/121 | | 3031/3037 | |  |  | |  | |  | IMV 9/121 | | IMV 249/3037 | |  | 5/121 | | 157/3037 | | |
| Chia | Singapore | Alpha, Beta, Delta, Gamma | mRNA |  |  |  |  |  | 2/71δ | | 27/130δ | |  | 0/71  (IMV 0/71)δ | | 7/130  (IMV 2/130)δ | |  | 0/71δ | | 2/130δ | |
| Thangaraj | India | Delta, Kappa, Alpha, Beta | ChAdOx1 COVAXIN |  |  |  |  |  | 7/104 | | 34/176 | |  |  |  |  |  |  | 0/104 | | 7/176 | |
| Butt | Qatar | Delta and Beta | BNT162b2 |  |  |  |  |  |  | |  | |  |  |  |  |  |  | Severe+ death: 48/456 α | | Severe + death: 121/456 α | |
| Shamier | Netherland | Alpha, Beta, Delta and Gamma | mRNA  Astra  J&J | 0/161 | |  |  |  | 0/161 | |  | |  | 0/161 | |  | |  | 0/161 | |  | |
| Butt | USA | Alpha, Beta and Delta | mRNA |  |  |  |  |  |  | |  | |  |  |  |  |  |  | Severe+ death: 50/250 α | | Severe+ death: 53/250 α | |
| Aslam | USA | Not specified | mRNA  J&J |  |  |  |  |  |  | |  | |  |  |  |  |  |  | 0/4 infected α | | 2/59 infected α | |
| Christensen | USA | Delta and Alpha | mRNA  J&J | 800/3088 | 96/258 | 6406/13619 | |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
| Bierle | USA | Delta | mRNA  J&J | 23/201δ | | 53/429 δ | |  | 11/201 δ | | 38/429 δ | |  |  |  |  |  |  |  |  |  |  |

HW, healthcare worker; IMV, invasive mechanical ventilation; NIPPV, non-invasive positive pressure ventilation; ECMO, extracorporeal membrane oxygenation

All data are expressed as n, n/N

¶ Pre-Delta means any variant other than the Delta variant that was dominant before the Delta variant was most likely..  
α, Variants other than delta  
δ, data from delta variant only

**Table 3. Patients’ demographic in included studies**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Gender(Male)§** | | **Age** | | **Race** | | **Hypertension** | | **Diabetes** | | **Chronic lung disease** | | **Immunosuppressed** | | **Transplants** | |
| Author | Category | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated | Breakthrough | Unvaccinated |
| Bosch | Hospitalized patients | 82/126 | 499/839 | 69.1±13.9 | 59.6±16.0 | Hispanic 6/126 | Hispanic 55/839 | 80/126 | 433/839 | 39/126 | 190/839 | 93/126 | 586/839 | 42/126 | 128/839 | 28/126 | 57/839 |
| Tenforde | Hospitalized | 176/314 | 838/1669 | 67(55-74) | 53(40-63) | Hispanic 55/314 black 55/314 white 201/314 other 14/314 | Hispanic 381/1669 black453/1669 white 17/1669 other 118/1669 | 236/314¶ | 814/1667¶ | 112/314 | 425/1667 | 100/314 | 327/1667 | 128/314† | 191/1667† |  |  |
| Chia | Infected | 27/71 | 67/130 | 56(39-64) | 39.5(30-58) |  |  | 14/71 | 28/130 | 5/71 | 28/130 |  |  |  |  |  |  |
| Thangaraj | Infected | 66/113 | 109/185 | 54(42-64)  n=113 | 47(33-57)  n=185 |  |  | 50/112⁂ | 71/182⁂ |  |  |  |  |  |  |  |  |
| Bahl | Infected | 60/129 | 5130/10880 | 70.3±16.4 | 52.1±18.2 | Black  13/129  White  108/129 | Black  3452/10880  White  6467/10880 |  |  |  |  |  |  |  |  |  |  |
| Butt⁑ | Infected | 277/456 | 277/456 | 45(36-59.8) | 45(36-59.8) | Qatari 144/456 | Qatari 144/456 | 140/456 | 114/456 | 116/456 | 108/456 | 30/456 | 23/456 | 20/456 | 5/456 | 8/456 | 4/456 |
| Aslam | Infected | 587/912 | 802/1239 | 59.4±13.8 | 55.3±13.8 |  |  |  |  |  |  |  |  |  |  |  |  |
| Liu | Infected | 88/198 | 5153/14164 | 58.5±20.34 | 59.1±18.86 | black 30/198  white 88/198  Hispanic 58/198 | black1851/14164  white 325/14164  hispanic3932/14164 |  |  |  |  |  |  | 90/198 | 5133/14164 | 10/198 | 366/14164 |

All data were presented as n, n/M, median(interquartile range) or mean(±standard deviation)

**§** The proportion of male patinets were expressed, for instance, ‘82/126 in Bosch et al in breakthrough infection means 82 male among 126 total patients’.  
¶ Cardiovascular disease : Hypertension, Heart failure, Peripheral vascular disease, Prior myocardial infarction, Cardiac arrhythmias, Valvular heart disease  
†active solid organ cancer, active hematologic cancer HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn disease or ulcerative colitis.  
⁂ any comorbid condition  
⁑ Propensity score matched study(age, gender, race, comorbidity, reason for testing)

Tables









